Healthcare payers make decisions on funding for treatments for diseases, such as chronic-obstructive pulmonary disease (COPD), on a population level, so require evidence of treatment success in appropriate populations, using usual routine care as the comparison for alternative management approaches. Such health outcomes evidence can be obtained from a number of sources.
INTRODUCTION

PROSPECTIVE CLINICALTRIALS
The ' gold standard' method for obtaining evidence of treatment success is usually taken as the randomized controlled prospective clinical trial. Such studies are highly valued by those seeking best possible evidence as they are designed to test a defined hypothesis in a way that reduces bias and controls for confounders, though at considerable cost. The results from randomized clinical trials often show highly significant differences in treatment approaches.Yet the value of these results as evidence for decision-makers can be questioned.
Restricted entry criteria ensure a homogeneous study population but limit the ability to generalize to real life contain, but they provide the outcomes data required by patients, providers and policy makers to inform decisions on the management of COPD (Table 3) . 
RETROSPECTWE AND OBSERVATIONAL STUDIES
